The zygotic genes
end-1 and
end-3 together are required to specify the endoderm progenitor, the E cell. Their expression is restricted to the E blastomere and ectopic expression of either gene is sufficient to convert non-E lineages to an E-like fate. Genetic screens have identified maternal factors, including SKN-1 and POP-1, that are involved in mesendoderm specification and correct
end-1,3 expression. To isolate regulators of
end-1 that were missed in genetic screens, we used mass spectrometry to identify a transcription factor, PLP-1 (pur alpha like protein) that directly binds to the
end-1 promoter and that is similar to the mammalian transcription factor pur alpha. RNAi of
plp-1 results in embryos that fail to form a pharynx. Some of the arrested embryos produce extra intestine, suggesting a transformation of non-E lineages to an E-like fate. A very impenetrant gutless phenotype is also observed, which is greatly enhanced in mutants defective in the endoderm-inducing Wnt pathway. However,
plp-1 RNAi does not enhance the gutless phenotype observed in mutants in the MAP kinase pathway, which converges with the Wnt pathway to regulate endoderm development, suggesting that
plp-1 may function in the latter pathway. To understand how
plp-1 might act both positively and negatively on
end-1 expression, we have examined the in vitro binding characterisics of PLP-1 and its possible post-translational modifications. PLP-1 binds to a putative Lef-1 binding site, which is required for activation of a minimal
end-1 promoter. Surrounding this region, the
end-1 DNA apparently adopts a secondary structure in vitro that can be cleaved with an endonuclease specific to cruciform structures. Deletion of the Lef-1 site results in loss of this secondary structure and PLP-1 binding activity. The affinity of PLP-1 for this site appears to be regulated by phosphorylation, as demonstrated by the loss of PLP-1 binding activity when early embryonic nuclear extract is treated with a non-specific phosphatase and by the ability of the extract to phosphorylate recombinant PLP-1 protein. A candidate kinase that might phosphorylate PLP-1 is the nemo-like kinase LIT-1, since it is a component of the MAPK pathway. Consistent with this possibility, we find that in
lit-1 mutants, PLP-1 only weakly localizes to the nucleus with a more diffuse staining pattern throughout the cell, unlike in normal embryos in which it is strongly nuclear-localized.